Merck results beat expectations despite a big drop in sales of Covid antiviral treatment
Despite the drop in molnupiravir sales, Merck's revenue and adjusted earnings for the first quarter beat Wall Street's expectations.
Despite the drop in molnupiravir sales, Merck's revenue and adjusted earnings for the first quarter beat Wall Street's expectations.
What's Your Reaction?
